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Treatment for diseases of the airways is largely palliative, being directed in the main towards the reduction of acute exacerbations and limitation of the impact of disease on daily life. For the purposes of measurement, the latter may be regarded as a series of different activities, some of which are listed in the right hand box of figure 1. Disturbance of these activities may result from a range of pathophysiological disorders, which mediate their effects through a limited number of symptoms. Despite the palliative nature of treatment for airways disease, relatively little regard has been paid to the activities listed in the right hand box of figure 1 as possible measures of therapeutic outcome. It is generally assumed that a measured improvement in the disease processes shown on the left of figure 1 will be accompanied by improved health and wellbeing. This assumption is based on the belief that the arrows in this figure imply a direction of causality that holds both during the development of a disease and with the response to treatment. In fact, there is surprisingly little scientific evidence that treatment improves the overall state of patients with a chronic disease. Before we consider treatment, the processes by which disease activity in the lungs leads to the disruption of daily living are worth examining. The To illustrate this problem, it is worth looking more closely at the effects of breathlessness. Figure 1 suggest a simple linear sequence, but the scheme in figure 2 is more realistic. This model is not complete, and I make no claim that it provides profound insights; but there is experimental evidence for most of the links between the boxes, and other links are reasonable hypotheses based on current knowledge. The figure 2 is presented hierarchically.
At each level additional factors are fed in and interact with signals coming up from below. These factors may be unrelated to the basic disease, yet may modulate the signal produced by the underlying pathological process quite profoundly. Without knowledge of the operating characteristics of the individual processes and information on the size of the outside influences, we could not predict the magnitude of the disturbances at the top of this system from a knowledge of a disturbance at the bottom, no matter how accurately it was measured.
Breathlessness: the link between lung disease and disability Quality of life measurement is concerned with the events at the top of figure 2, but some intermediate steps must be considered. Breathlessness is the critical link between lung disease and ensuing disability, yet the factors that determine it are poorly understood. Studies during standardised ergometer exercise tests in normal subjects have shown wide variations between individuals in the intensity of perceived dyspnoea in relation to ventilation.'13 The reasons for this diversity are still unknown. There is also evidence that the level of distress that normal subjects associate with their breathlessness during exercise is unrelated to their perception of its intensity. 4 Comparable studies in patients have not been performed and we do not know which aspects of breathlessness limit daily activity. The generation of breathlessness is a critical process in the production of impaired exercise tolerance, but currently we can neither predict an individual patient's level of breathlessness nor quantify the effect of changes in lung function on it. Advantages of standardised health questionnaires General health measures such as the Sickness Impact Profile and Quality of Wellbeing Scale are standardised. Each patient completes exactly the same questionnaire, which is always scored in the same way. Both of these questionnaires produce a single index or summary score, and with the Sickness Impact Profile a profile of category scores may also be calculated to provide a more detailed description of the disturbances of daily life. Such profiles for patients with differentlevelsofairflowlimitation have been published.252729 The advantage of standardised health scores is that they allow comparisons not only between subjects within a given study but across study populations, as shown in figure 3 . Furthermore, if a standardised questionnaire were sufficiently sensitive, its score would allow direct comparisons of efficacy between therapeutic trials. Some of the solutions to the problem of designing a sensitive questionnaire have overlooked this property. Examples include some otherwise good and successful measures. One of these is the Mahler transition score for breathlessness,12 which measures one symptom only, though an important and disabling one. Therapeutic benefit from theophylline3' and targeted muscle training3" has been demonstrated with this measure. As its name suggests, this measure grades changes in symptoms with respect to each patient's baseline state, so it allows only semiquantitative comparisons between responses from different patients or studies. The first quality of life measure developed specifically for chronic airflow limitation, the Chronic Respiratory Questionnaire,32 is also not completely standardised. It has the worthy property of allowing patients partially to tailor the questionnaire to suit their state, but unfortunately this "individualisation" does not allow a standardised score to be calculated. Use ofthis measure has shown quality oflife benefits of bronchodilators,33 but direct comparisons of efficacy between this and other studies in which the same questionnaire may be used will not be possible. This problem has been exemplified recently in a study using the chronic respiratory questionnaire to compare patients with chronic obstructive airways disease and cystic fibrosis. In that study the authors had to adjust the scores from the patients with cystic fibrosis to allow comparisons with the patients with chronic obstructive airways disease because the former identified fewer areas of daily life causing dyspnoea.34
Disease specific measures ofquality oflife There is a need for a standardised and sensitive measure of the impact of chronic airways diseases on the daily life and perceived wellbeing of patients with these conditions. As discussed previously, comprehensive coverage of many different diseases may render the measure too insensitive for specific disease states. Sensitivity may be increased by limiting In one study of patients with a mean post-bronchodilator FEV, of 53% predicted 47% of the patients had an anxiety score at or above the borderline of clinical significance on the hospital anxiety and depression scale and 29% had depression scores in this range.25 A further study recorded moderate levels of anxiety on the basis of the Speilberger index, and borderline levels of depression according to the Beck depression inventory.42 In younger asthmatic patients anxiety levels have been reported to be higher than in normal subjects.4" A correlation between psychological morbidity and poor spirometric results has been found in patients with chronic obstructive airways disease"2 and psychological state may influence patients' reporting of respiratory symptoms. 26 The latter has important implications for quality of life measurement. Anxiety and depression scores were found to correlate with the symptoms score from the St George's respiratory questionnaire. To analyse this further, responses to the MRC respiratory questionnaire items about the frequency of cough and wheeze were included with the anxiety or depression score in a multivariate statistical model. '7 In this model, in which the St George's symptoms score was the dependent variable, respiratory symptoms were the dominant correlates and correlations with mood scores were much weaker. A similar picture was seen with the St George's activity score. Correlations with anxiety and depression were found with this score, but these correlations became weaker when the MRC dyspnoea score was included in a multivariate model and the dyspnoea score then became the dominant correlate. In contrast, correlations between mood score and the impacts score of the St George's questionnaire remained strong, even in multivariate models that included other powerful correlates of the impact score, such as responses to MRC questionnaire items concerned with dyspnoea and frequency of wheeze. Mood state scores appear therefore to correlate with the symptoms and activity sections of the St George's questionnaire, largely through a shared association with measures of disease activity, including symptom severity, physical impairment, and perceived disability. The impacts section contains items that correlate with anxiety independently of other disease related factors. Clearly relations between anxiety, depression, and the perception of health are complex and still poorly delineated.
Quality of life questionnaires in clinical trials "Quality of life" measures are now beginning to appear in clinical trials, but are they anything more than a marketing ploy? I believe that they are. Most people would agree, that with a lifelong disease, a major requirement of any therapy should be a clear demonstration of its beneficial effects on daily life and wellbeing. As discussed earlier, it is not possible to make reliable predictions of a patient's disability or impaired wellbeing from measurements of airways function. There is as yet, limited data concerning the relationship between changes in spirometry following therapy and changes in health, but the available evidence suggests a generally poor correlation. In patients with asthma studied over an eighteen month interval, changes in FEV, correlated with changes in quality of life measured with the quality of wellbeing scale (r2 = o040). '7 In a study of bronchodilators in patients with chronic obstructive airways disease there was a significant correlation (r2 = 0 30) between FEV, and quality of life as determined by the chronic respiratory questionnaire." In both of these studies the correlations, though moderately good, were too low to allow accurate prediction of the quality of life score from the FEVI. In another study in patients with chronic obstructive airways disease over a one year interval changes in quality of life as assessed by the St George's respiratory questionnaire score correlated poorly with change in FEV, but rather better with the patient's walking distance or the MRC dyspnoea score.'7 A study on the effect of salbutamol in chronic obstructive airways disease found a very low and non-significant correlation between changes in spirometric values and perceived breathlessness."3 Finally, in a study using theophylline, breathlessness improved but with no significant change in spirometric results, arterial blood gas tensions, or walking distance.'0 Clearly we cannot assume that improvement in subjective health or disability will accompany a measured improvement in airways function.
Health questionnaires were developed as a scientific response to the problem of quantifying aspects of disease severity that could not be assessed by existing measures Quality of life measures in audit and routine practice Quality of life measures are clearly suitable for auditing the outcome of medical care in terms of patients' perceived health, but they should not be confused with measures of "satisfaction".45 Measurement of satisfaction is a process used to assess the success with which the supplier or a process meets or exceeds the requirements of a consumer or client. It has to be scored largely in relative terms. A discussion of the intriguing and complex relations between satisfaction and perceived health and wellbeing is beyond the remit of this review. It should be realised, however, that in the context of medical audit there may be significant differences between the conclusions obtained from an audit using a quality of life measure and one using a satisfaction index. Consider these two statements: "In this audit 80% of patients were satisfied with their improvement with treatment" and "In this audit the mean baseline health score of the patients was Limitations of quality of life measures in airways disease Questionnaires for quality of life measurement should be applied only to diseases in which their use has first been validated. Even when appropriately selected the presence of intercurrent disease could be a confounding factor. Unreliable results may be produced if quality of life measures are used incorrectly. In general, these questionnaires are easy to use and fairly robust, but they should be handled with the same care and attention to detail as any other instrument. One perceived limitation may be the rate of change with treatment. By comparison with measurement of disturbances close to the underlying pathological process (as illustrated in figs 1 and 2) quality of life scores may respond to therapeutic intervention quite slowly. This is not due to an inherent weakness in the questionnaires but is a reflection of the influence of factors that can modulate the impact of disease on the patient's life. Many of these factors may be unrelated to the underlying disease process and therefore would not be directly influenced by treatment. Disuse atrophy of leg muscles due to exercise limitation resulting from breathlessness is an obvious example. Instant cure would not immediately return the patient's life to its premorbid state. Finally, expectations of quality of life measurement should be realistic. If a treatment has little measurable influence on the underlying disease processes or on processes close to it, it is unlikely to improve subjectively perceived wellbeing unless it also possesses direct pyschoactive properties, as may be the case with oral corticosteroids.42 Good quality of life measures are well validated instruments that provide hard data on health. They are not magic wands to be used when other measurements have shown little benefit from the treatment under study.
